Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 4/20 | 0.35 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.34 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.33 |
| ▸ | CASP1 | P29466 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | PTPN7 | P35236 | 1/20 | 0.32 |
| ▸ | DUSP3 | P51452 | 1/20 | 0.32 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.31 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.31 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.30 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1172949 | 1.00 | KDM1A (0.35) | KDM1AKDM1BDGAT1CASP1SMN1; SMN2 | |
| SCHEMBL1172948 | 1.00 | KDM1A (0.35) | KDM1AKDM1BDGAT1CASP1SMN1; SMN2 | |
| SCHEMBL16229519 | 0.82 | KDM1A (0.33) | KDM1AKDM1B | |
| SCHEMBL361762 | 0.77 | DGAT1 (0.38) | KDM1AKDM1BDGAT1CASP1SMN1; SMN2 | |
| SCHEMBL12467196 | 0.76 | KMT2A (0.42) | KDM1AKDM1BDGAT1SMN1; SMN2AAK1 | |
| SCHEMBL14903792 | 0.76 | KMT2A (0.42) | KDM1AKDM1BDGAT1SMN1; SMN2AAK1 | |
| SCHEMBL247850 | 0.76 | DGAT1 (0.37) | KDM1AKDM1BDGAT1CASP1PTPN7 | |
| SCHEMBL1173372 | 0.76 | DGAT1 (0.37) | KDM1AKDM1BDGAT1CASP1PTPN7 | |
| SCHEMBL1173257 | 0.76 | DGAT1 (0.37) | KDM1AKDM1BDGAT1CASP1PTPN7 | |
| SCHEMBL16077142 | 0.75 | KDM1A (0.37) | KDM1AKDM1BDGAT1PTPN7DUSP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2619207-B1 | 4,7-Dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2014-11-12 | — | — | EP | disclosed |
| US-8609660-B2 | 4,7-dihydro-pyrazolo[1,5-a]pyrazin-6-ylamine derivatives useful as inhibitors of beta-secretase (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2013-12-17 | — | — | US | disclosed |
| EP-2619207-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | Janssen Pharmaceutica, N.V. (BE) | 2013-07-31 | — | — | EP | disclosed |
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (US) | 2013-07-25 | — | — | US | disclosed |
| WO-2012038438-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | JANSSEN PHARMACEUTICA NV (BE) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190318-A1 | 4,7-DIHYDRO-PYRAZOLO[1,5-a]PYRAZIN-6-YLAMINE DERIVATIVES USEFUL AS INHIBITORS OF BETA-SECRETASE (BACE) | BACE2, BACE1, PSEN2 | KDM1A 3522/4885KDM1B 2902/4885DGAT1 3155/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.